Ignite Creation Date:
2024-05-06 @ 3:51 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04783545
Status:
COMPLETED
Last Update Posted:
2022-04-28
First Post:
2021-02-26
Brief Title:
Phase I Study of VLX-1005 in Healthy Subjects
Sponsor:
Veralox Therapeutics
Organization:
Veralox Therapeutics
Study Overview
Official Title:
A Two-part Double-blind Placebo-controlled Phase I Study of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Intravenous VLX-1005 in Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2022-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The principal objective of this study is to describe the safety of and tolerability to single and multiple doses of VLX-1005 in healthy subjects following intravenous IV administration
Other exploratory objectives are
To evaluate the pharmacokinetics and pharmacodynamics of VLX-1005 following IV administration
Other exploratory objectives are
To evaluate the pharmacokinetics and pharmacodynamics of VLX-1005 following IV administration
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None